NNC0114-0006 + placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Systemic Lupus Erythematosus
Trial Timeline
Sep 1, 2012 → Feb 1, 2014
NCT ID
NCT01689025About NNC0114-0006 + placebo
NNC0114-0006 + placebo is a phase 1 stage product being developed by Novo Nordisk for Inflammation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01689025. Target conditions include Inflammation, Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01751152 | Phase 2 | Completed |
| NCT01647451 | Phase 2 | Completed |
| NCT01689025 | Phase 1 | Terminated |
| NCT01565408 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammation